A Phase II Study of Ibrutinib Plus Rituximab Followed by Venetoclax and Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: Window II Protocol
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary) ; Ibrutinib (Primary) ; Methotrexate (Primary) ; Rituximab (Primary) ; Venetoclax (Primary) ; Vincristine (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 24 Oct 2019 Planned End Date changed from 18 May 2023 to 22 May 2021.
- 21 May 2019 Planned End Date changed from 22 Apr 2021 to 18 May 2023.
- 07 May 2019 Status changed from not yet recruiting to recruiting.